Rheumatoid Arthritis Market

Key Highlights:

• The Rheumatoid Arthritis market size of 7MM was USD 27 billion in 2021 and is projected to grow during the forecast period (2022-2032).
• The total prevalent population of Rheumatoid Arthritis in the 7MM comprised 4,724,978 cases in 2021 and is projected to increase during the forecast period.
• Rheumatoid Arthritis Companies like GlaxoSmithKline, Taisho Pharmaceutical, and R-Pharm with their key candidates are in the registrational or late clinical stage.
• Rheumatoid Arthritis companies like Pfizer, Acalris Therapeutics, Abivax, Istesso, Cyxone, and several others in Phase II clinical development stage with their investigational candidates.

Request a sample to unlock CAGR for Rheumatoid Arthritis Market Report

DelveInsight's “Rheumatoid Arthritis Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Rheumatoid Arthritis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Rheumatoid Arthritis market size from 2019 to 2032. The report also covers current Rheumatoid Arthritis treatment practices/algorithms, and unmet medical needs to curate the best of the opportunities and assess the market’s underlying potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain), and the United Kingdom
• Japan

Study Period: 2019-2032

Rheumatoid Arthritis Disease Understanding and Treatment Algorithm

Rheumatoid Arthritis Overview

Rheumatoid Arthritis is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. Rheumatoid Arthritis is the result of an immune response in which the body's immune system attacks its own healthy cells and the specific causes of Rheumatoid Arthritis are still unknown.

Rheumatoid Arthritis is more common in women and about 75% of Rheumatoid Arthritis patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, Rheumatoid Arthritis can start at any age.

Rheumatoid Arthritis is a chronic disease that causes joint pain, stiffness, swelling, and decreased movement of the joints. Small joints in the hands and feet are most commonly affected. Sometimes Rheumatoid Arthritis can affect other organs such as the eyes, skin, or lungs.

Rheumatoid Arthritis Diagnosis

Typically, Rheumatoid Arthritis is diagnosed by a combination of the patient's symptoms, results of the doctor´s examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of Rheumatoid Arthritis-specific autoantibodies.

Rheumatoid Arthritis Treatment

Conventional DMARDs are a group of drugs (i.e., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) that have been shown to affect the underlying cause of Rheumatoid Arthritis by damping down over-activity of the immune system, which helps to ease pain, swelling, and stiffness, and prevent changes occurring within the joint. Among csDMARDS, methotrexate (MTX) is considered a part of the first treatment strategy. MTX remains the anchor drug in Rheumatoid Arthritis; along with usage as monotherapy, it is also the basis for combination therapies, either with GC or with other csDMARDs, bDMARDs, or tsDMARDs.

Patients refractory to csDMARDS or with severe symptoms are usually treated with a wide variety of biologics DMARDs classes like anti-TNF, T-cell inhibitors, B-cell Inhibitor, Interleukin Inhibitors and targeted synthetic DMARDs like JAK Inhibitors.

Rheumatoid Arthritis Epidemiology

The Rheumatoid Arthritis epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Rheumatoid Arthritis, total diagnosed prevalent cases of Rheumatoid Arthritis, gender-specific prevalent cases of Rheumatoid Arthritis, age-specific prevalent cases of Rheumatoid Arthritis, severity-specific prevalent cases of Rheumatoid Arthritis, patients on targeted therapies of Rheumatoid Arthritis, line-wise treated cases of Rheumatoid Arthritis in the 7MM market covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032.

Key Findings

This section provides a glimpse of the Rheumatoid Arthritis epidemiology in the 7MM

Country Wise- Rheumatoid Arthritis Epidemiology

The epidemiology segment provides the Rheumatoid Arthritis epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

• The total prevalent population of Rheumatoid Arthritis in the 7MM comprised 4,724,978 cases in 2021 and is projected to increase during the forecast period.
• The total diagnosed prevalent cases of Rheumatoid Arthritis in the US were 1,256,779 in 2021
• The United States contributed to the largest diagnosed cases of Rheumatoid Arthritis, accounting for ~ 30% of the 7MM in 2021.
• Among EU4 countries, Germany accounted for the highest number of Rheumatoid Arthritis cases, whereas France accounted for the lowest number of cases in 2021.
• In Japan, the total diagnosed prevalent population of Rheumatoid Arthritis was 924,571 in 2021.
• In 2021, males and females accounted for 301,627 and 955,152 cases respectively in the United States.
• In the United States, the total age-specific prevalent cases of Rheumatoid Arthritis were 61,834, 134,098, 297,605, 438,365, and 324,877 cases for the age group 18-34 years, 35-44 years, 45-54 years, 55-64 years, and ≥65 years in 2021.
• In 2021, 377,034 mild cases, and 879,745 moderate-to-severe cases were observed in the United States

Rheumatoid Arthritis Drug Chapters

Drug chapter segment of the Rheumatoid Arthritis market report encloses the detailed analysis of Rheumatoid Arthritis marketed drugs and late-stages (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Rheumatoid Arthritis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, the latest news, and press releases.

Marketed Rheumatoid Arthritis Drugs

OLUMIANT (barticinib): Eli Lilly/Incyte Corporation

OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe Rheumatoid Arthritis who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis. Currently, OLUMIANT is conducting a Phase II trial (NCT04870203) in combination with adalimumab in Rheumatoid Arthritis.

RINVOQ (upadacitinib): AbbVie

RINVOQ- an AbbVie product is a prescription medicine used to treat adults with moderate to severe Rheumatoid Arthritis in whom methotrexate did not work well or could not be tolerated. In August 2019, AbbVie announced that the US FDA has approved RINVOQ for the treatment of adults with moderately to severely active Rheumatoid Arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, the European Commission (EC) granted approval to RINVOQ for the treatment of adult patients with moderate to severely active Rheumatoid Arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Whereas, in January 2020, the Japan Ministry of Health Welfare and Labor approved the use of RINVOQ for the treatment of adult patients with moderate to severely active Rheumatoid Arthritis.

HUMIRheumatoid Arthritis (adalimumab): AbbVie

HUMIRheumatoid Arthritis is a very renowned tumor necrosis factor blocker. HUMIRA is a recombinant human IgG1 monoclonal antibody created using phage display technology resulting in an antibody with human-derived heavy and light chain variable regions and human IgG1 constant regions. In December 2002, the US FDA granted approval to market HUMIRA. In September 2003, HUMIRheumatoid Arthritis received approval from the EC for the treatment of adult Rheumatoid Arthritis in Europe. Whereas, in April 2008, the Japanese Ministry of Health, Labor, and Welfare (MHLW) approved HUMIRheumatoid Arthritis for the treatment of Rheumatoid Arthritis in patients with inadequate response to conventional therapy.

ENBREL (etanercept): Immunex/Amgen

ENBREL is a drug that reduces the signs and symptoms of moderate to severe Rheumatoid Arthritis, such as joint swelling, pain, fatigue, and the length of morning stiffness. It is also prescribed for psoriasis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. It is a biological drug that is in a class of drugs called anti-TNFs or TNF blockers. In May 1999, ENBREL was approved today by the US FDA for the treatment of moderately to severely active polyarticular-course juvenile Rheumatoid Arthritis (JRA) in patients who have had an inadequate response to one or more disease-modifying medicines. In February 2000, EC approved the use of etanercept for the treatment of moderate to severe Rheumatoid Arthritis. Whereas, in January 2005, the Japan Ministry of Health and Welfare approved ENBREL for the treatment of patients dealing with Rheumatoid Arthritis.

ORENCIA (abatacept): Bristol Myers Squibb

ORENCIA is an immunomodulator that disrupts the continuous cycle of T-cell activation that characterizes Rheumatoid Arthritis. It is a selective T-cell co-stimulation modulator. BMS and Ono jointly developed and commercialized ORENCIA in Japan. BMS is responsible for the order fulfillment and distribution of the intravenous formulation and Ono is responsible for the subcutaneous formulation. Both formulations are jointly promoted by both parties with assigned customer accounts and BMS is responsible for the product supply. ORENCIA experienced a reimbursement decrease in July 2021 due to the new ASP calculation methodology. In July 2011, the US FDA approved a subcutaneous formulation of ORENCIA for the treatment of adults with moderate to severe Rheumatoid Arthritis.

Note: Detailed current therapies assessment will be provided in the full report of Rheumatoid Arthritis

Emerging Rheumatoid Arthritis Drugs

Otilimab (GSK3196165/MOR103): GlaxoSmithKline

Otilimab (previously known as GSK3196165) is under the development process by GlaxoSmithKline in Phase III. It is a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that plays a central role in a broad range of immune-mediated diseases, including rheumatoid arthritis. GM-CSF acts on cells, including macrophages (an immune cell type that plays a key role in the inflammatory process), leading to inflammation, joint damage, and pain. Findings of the BAROQUE study have shown that major secondary endpoints including a number of traditional measures to assess the efficacy of GSK165 were improved in line with the DAS28 (CRP) reduction. For DAS28 (CRP) < 2.6 at Week 24 (the primary endpoint of the study), a greater proportion of patients achieved efficacy although this did not reach statistical significance at Week 24 (16% for GSK165 180mg vs. 3% for placebo, p = 0.134).

Zunsemetinib (ATI-450): Aclaris Therapeutics

Zunsemetinib, an investigational drug formerly known as CDD-450, is a unique p38α MAPK–MK2 pathway selective inhibitor used to uncover the function of this protein complex in inflammasome priming signals. Importantly, ATI-450 is as efficacious as global p38α MAPK inhibitors in decreasing inflammation in disease models; ATI-450 selectively blocks p38α MAPK activation of the proinflammatory kinase MK2 while sparing p38α activation of other effectors such as PRAK and ATF2. Zunsemetinib has been adopted as the nonproprietary name for ATI-450. Aclaris Therapeutics is currently conducting a Phase IIb dose-ranging trial to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses (20 mg and 50 mg twice daily) of zunsemetinib in combination with methotrexate in subjects with moderate to severe Rheumatoid Arthritis. Aclaris anticipates increasing the size of the patient population from approximately 195 to approximately 240 subjects and expects topline data in 2023.

ABX464: Abivax

ABX464 is an oral treatment, the first-in-class small molecule being developed by Abivax that binds to the cap-binding complex (CBC), which rests on the RNA molecule. By binding to the CBC, ABX46 downregulates pro-inflammatory cytokines and chemokines, such as tumor necrosis factor-alpha (TNFα), interleukin, 6, and monocyte chemoattractant protein 1—thus, stopping inflammation. In the Phase IIa study, ABX464-301, (NCT04049448) positive top-line data is reported by the company, and one-year data from this study is expected in Q1 2022. Abivax is preparing to start a clinical Phase IIb program in Rheumatoid Arthritis in early 2022.

PF-06650833: Pfizer

PF-06650833 is in the clinical development process by Pfizer. It is a selective, highly potent, small molecule, reversible inhibitor of IRAK4. Currently, a Phase II (NCT04413617), 24-week randomized, double-blind, parallel-group, multicenter study is ongoing to assess the efficacy and safety of PF-06650833, PF-06651600, and tofacitinib alone and in combination in participants with moderately-severely active rheumatoid arthritis with an inadequate response to methotrexate.

Rabeximod (Rob 803): Cyxone

Rabeximod is an orally available drug with a unique mechanism of action that selectively targets the inflammatory macrophage, a type of white blood cell that is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in rheumatoid arthritis. Rabeximod has been extensively studied in Phase I and Phase II clinical trials. Safety studies reveal a favorable safety profile compared to anti-rheumatoid arthritis drugs such as anti-TNFα monoclonal antibodies and oral JAK inhibitors. In June 2022, Cyxone received a response from a Type B pre-IND meeting with the US FDA. The response from the FDA facilitates for Cyxone to continue planning the Phase IIb study with Rabeximod in Rheumatoid Arthritis.

Note: Detailed emerging therapies assessment will be provided in the final report.

Rheumatoid Arthritis Market Outlook

Rheumatoid Arthritis is an autoimmune disease for which several effective treatment options are present. Currently, there are three primary treatment options for severe and advancing Rheumatoid Arthritis which include DMARDs, NSAIDs, and corticosteroids. Early treatment of Rheumatoid Arthritis patients with DMARDs significantly decreases these complications. Methotrexate is an excellent, economical first-line DMARD used to treat a majority of Rheumatoid Arthritis patients. While most patients respond well to MTX, many continue to have active disease.

DMARDs are immunosuppressive and immunomodulatory agents and are classified as either conventional DMARDs or biologic DMARDs. Biologic DMARDs are rapidly effective in retarding the progression of joint damage caused by Rheumatoid Arthritis. Tumor necrosis factor (TNF) is a messenger protein that promotes inflammation in joints. Biologic medications such as ENBREL (etanercept), REMICADE (infliximab), HUMIRA (adalimumab), SIMPONI (golimumab), and CIMZIA (certolizumab pegol) are all TNF inhibitors that prevent the recruitment of the cells that cause inflammation, bringing rapid symptom relief. It is worth noting that, prior to 2009, ENBREL, REMICADE, and HUMIRheumatoid Arthritis were the only three TNF inhibitors dominating the market of Rheumatoid Arthritis in the United States. Apart from this, T-cell costimulatory blocking agents (ORENCIA), B-cell depleting agents (RITUXAN), interleukin-6 (IL-6) inhibitors (ACTEMRA), and interleukin-1 (IL-1) receptor antagonists (KINERET), have also been approved over the past few years for the management of Rheumatoid Arthritis.

HUMIRA is one the top-selling drugs in the world and the strength of AbbVie. It was the first human monoclonal antibody to be approved for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active Rheumatoid Arthritis who have had an insufficient response to one or more traditional DMARDs.

Over the past few years, improvements in the field of Rheumatoid Arthritis have been observed however there is a necessity to have a profound understanding of the disease, and its unmet needs. Reflecting on these issues, the significance of dedicating resources to R&D is also imperative. To achieve great success in Rheumatoid Arthritis pricing policies must be considered because this further will help in the launch of a product that is truly attractive and appropriate to the market it is being launched into. All these factors help in building a strong product-market fit. At present, several companies have indulged themselves to initiate clinical trials that investigate new treatment options or study how to use existing treatment options better. The current developmental pipeline for Rheumatoid Arthritis is very robust. The dynamics of the Rheumatoid Arthritis market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world

Companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], R-Pharm (Olokizumab) with their key candidates are in registrational or late clinical-stage. In addition to this, companies like Pfizer (PF-06650833, and PF-06651600), Acalris Therapeutics [ATI-450 (Zunsemetinib/CDD-450], Abivax (ABX464), Istesso (MBS2320), Cyxone [Rabeximod (Rob 803)], and several others in Phase II clinical development stage with their investigational candidates.

Key Findings

This section includes a glimpse of the Rheumatoid Arthritis in 7MM market.

• The total Rheumatoid Arthritis market size in the 7MM was USD 27 billion in 2021 and is projected to grow during the forecast period (2022-2032).
• According to the estimates, the highest Rheumatoid Arthritis market size is from the United States, in 2021 and is anticipated to grow at a CAGR of 2.8%.
• Among EU4 countries, Germany has the maximum revenue share in 2021 while Spain has the lowest market share.
• The Rheumatoid Arthritis market size in Japan was found to be USD 3 billion in 2021, which is expected to rise during the forecast period (2022-2032).

The United States: Rheumatoid Arthritis Market Outlook

The total market size of Rheumatoid Arthritis in the United States is expected to increase with a CAGR of 2.8% during the study period (2019–2032).

Japan: Rheumatoid Arthritis Market Outlook

The total Rheumatoid Arthritis market size in Japan is expected to increase with a CAGR of 0.5% during the study period (2019–2032).

Analyst Commentary

• Current Rheumatoid Arthritis therapies such as biological DMARDs showed promising results in treating Rheumatoid Arthritis patients, and market penetration is expected to be more in the future and is expected to drive market growth. Oral classes such as JAKi are also expected to contribute to the Rheumatoid Arthritis market growth due to patient convenience towards oral drugs.
• The geriatric population is a major end-user of Rheumatoid Arthritis drug treatment. The increase in the number of geriatric people leads to a high rate of ailments, which is likely to propel the demand for various drugs in the market.
• Despite the wide array of available treatments for Rheumatoid Arthritis, quality of life remains unmet across key domains such as pain, physical function, mental function, and fatigue.
• Currently, Istesso is exploring its TNF inhibitor drug, MBS2320, as an oral formulation. If approved, this will be the first oral TNF inhibitor and will create a good opportunity for the company. Similarly, Applied Molecular Transport and Akros Pharma/Japan Tobacco are developing oral formulations of IL-inhibitors, AMT-101, and JTE-051, for the treatment of Rheumatoid Arthritis.
• Since the pathophysiology of Rheumatoid Arthritis overlaps with that of other inflammatory diseases, most Rheumatoid Arthritis drugs will undergo label expansions into additional indications, such as ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, ulcerative colitis.
• Strict regulations on the usage of advanced therapies, such as in the UK (i.e., in patients with a DAS score >5.1), will limit the penetration of advanced therapies in the treatment of Rheumatoid Arthritis patients.
• Recently failure of many BTK inhibitors such as fenebrutinib, evobrutinib, acalabrutinib, and others will create fear for others companies exploring the BTK inhibitor.

Rheumatoid Arthritis Drugs Uptake

This section focuses on the rate of uptake of the potential Rheumatoid Arthritis drugs expected to get launched in the market during the study period 2019-2032. The analysis covers Rheumatoid Arthritis market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- Otilimab (GSK3196165)—a product of GlaxoSmithKline is a fully human monoclonal antibody that inhibits GM-CSF. It is currently being investigated in multiple Phase III clinical trials. This candidate is expected to enter the market in 2023. As per our analysis, Otilimab drug uptake in the US for Rheumatoid Arthritis is expected to be medium with a probability-adjusted peak share of 0.7% in the first line setting, years to peak would be 7 years.

Rheumatoid Arthritis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Rheumatoid Arthritis market report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Rheumatoid Arthritis emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders include MD, Ph.D. Rheumatologist at the University Hospital at Montpellier, Cardiff University School of Medicine, UK, and chief development officer of MorphoSys. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Rheumatoid Arthritis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Rheumatoid Arthritis market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers a descriptive overview of Rheumatoid Arthritis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into Rheumatoid Arthritis epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Rheumatoid Arthritis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Rheumatoid Arthritis market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Rheumatoid Arthritis market.

Report Highlights

• In the coming years, the Rheumatoid Arthritis market is set to change due to emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• As per DelveInsight’s analysis, on the basis of severity Rheumatoid Arthritis is categorized into mild, moderate, and severe.
• The report also encompasses other major segments, i.e., total prevalent cases of Rheumatoid Arthritis, total diagnosed prevalent cases of Rheumatoid Arthritis, gender-specific prevalent cases of Rheumatoid Arthritis, age-specific prevalent cases of Rheumatoid Arthritis, severity-specific prevalent cases of Rheumatoid Arthritis, patients on targeted therapies of Rheumatoid Arthritis, and line-wise treated cases of Rheumatoid Arthritis.
• Expected launch of potential therapies such as GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], R-Pharm (Olokizumab), Pfizer (PF-06650833, and PF-06651600), Acalris Therapeutics [ATI-450 (Zunsemetinib/CDD-450], Abivax (ABX464), Istesso (MBS2320), Cyxone [Rabeximod (Rob 803)], and others might change the landscape in the treatment of Rheumatoid Arthritis.
• The US FDA-approved drugs which are currently available include ENBREL, HUMIRA, CIMZIA, SIMPONI, MABTHERA/RITUXAN, ORENCIA, and others.

Rheumatoid Arthritis Report Insights

• Rheumatoid Arthritis Report Insights
• Rheumatoid Arthritis Patient Population
• Rheumatoid Arthritis Therapeutic Approaches
• Rheumatoid Arthritis Pipeline Analysis
• Rheumatoid Arthritis Market Size and Trends
• Rheumatoid Arthritis Market Opportunities
• Impact of upcoming Therapies

Rheumatoid Arthritis Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Rheumatoid Arthritis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Rheumatoid Arthritis Market
• Rheumatoid Arthritis Drugs Uptake

Rheumatoid Arthritis Report Assessment

• Current Rheumatoid Arthritis Treatment Practices
• Rheumatoid Arthritis Unmet Needs
• Pipeline Product Profiles
• Rheumatoid Arthritis Market Attractiveness
• SWOT
• Attribute Analysis

Key Questions

Rheumatoid Arthritis Market Insights:

• What was the Rheumatoid Arthritis market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Rheumatoid Arthritis total market size as well as market size by therapies across the 7MM during the study period (2019–2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Rheumatoid Arthritis market size during the study period (2019–2032)?
• At what CAGR, the Rheumatoid Arthritis market is expected to grow at the 7MM level during the study period (2019–2032)?
• What would be the Rheumatoid Arthritis market outlook across the 7MM during the study period (2019–2032)?
• What would be the Rheumatoid Arthritis market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Rheumatoid Arthritis Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of Rheumatoid Arthritis?
• What is the historical Rheumatoid Arthritis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What would be the forecasted patient pool of Rheumatoid Arthritis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Rheumatoid Arthritis?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Rheumatoid Arthritis during the study period (2019–2032)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2019–2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Rheumatoid Arthritis? What are the current treatment guidelines for the treatment of Rheumatoid Arthritis in the US, Europe, and Japan?
• What are the Rheumatoid Arthritis-marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Rheumatoid Arthritis?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Rheumatoid Arthritis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, and licensing activities related to the Rheumatoid Arthritis therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Rheumatoid Arthritis and their status?
• What are the key designations that have been granted for the emerging therapies for Rheumatoid Arthritis?
• What are the 7MM historical and forecasted market of Rheumatoid Arthritis?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Rheumatoid Arthritis.
• To understand the future market competition in the Rheumatoid Arthritis market and an insightful review of the SWOT analysis of Rheumatoid Arthritis.
• Organize sales and marketing efforts by identifying the best opportunities for Rheumatoid Arthritis in the US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Rheumatoid Arthritis market.
• To understand the future market competition in the Rheumatoid Arthritis market.